The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Beacon ...

Inherited eye disorders such as retinitis pigmentosa (RP) leave millions grappling with progressive vision loss. At the heart ...

A multidisciplinary team of researchers from the Istituto Italiano di Tecnologia (IIT-Italian Institute of Technology) and ...

An international team of researchers has identified new drug targets for therapies that could benefit patients with different forms of retinitis pigmentosa and other inherited retinal diseases.

In retinitis pigmentosa, the retina protein rhodopsin is often misfolded due to genetic mutations, causing retinal cells to die off and leading to progressive blindness. Small molecules to correct ...

The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The ...

Argus II is a novel healthcare technology that restores vision in RP patients. Improvements in visual acuity are expected to lead to improvements in patient self-confidence, decreasing their ...

The restoration of differential activity is fundamental for complex retinal response to light stimulation, which allows for more natural vision." "In pre-clinical models of retinitis pigmentosa ...